



## Chinook Therapeutics to Present at Upcoming Investor Conferences

November 17, 2021

SEATTLE, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming virtual investor conferences:

- **Piper Sandler 33<sup>rd</sup> Annual Virtual Healthcare Conference** – presentations will be available for registered attendees via the Piper Sandler conference site from November 22<sup>nd</sup> to December 2<sup>nd</sup>.
- **4<sup>th</sup> Annual Evercore ISI HealthCONx Conference** – fireside chat on Tuesday, November 30<sup>th</sup> at 4:45 pm EST

Chinook will participate in 1x1 meetings through Evercore ISI on Tuesday, November 30<sup>th</sup> and Wednesday, December 1<sup>st</sup> and through Piper Sandler on Thursday, December 2<sup>nd</sup>.

To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit the [Investors](#) section of Chinook's website. The archived webcasts will remain available for replay on Chinook's website for 90 days.

### About Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit [www.chinooktx.com](http://www.chinooktx.com).

### Contact:

Noopur Liffick

Vice President, Investor Relations & Corporate Communications

[investors@chinooktx.com](mailto:investors@chinooktx.com)

[media@chinooktx.com](mailto:media@chinooktx.com)



Source: Chinook Therapeutics, Inc.